News Releases

Date Title and Summary Additional Formats
Toggle Summary AVI BioPharma Announces Publication of Positive Results from New Class of Antibiotics Using NEUGENE Antisense Technology
PORTLAND, Ore., Aug 09, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq:AVII) today announced the publication of positive preclinical results from a new class of antisense-based antibiotics, called NeuBiotics. The article, titled "Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino
View HTML
Toggle Summary AVI BioPharma Reports Second Quarter Financial Results; Conference Call Begins Today at 11:00 a.m. Eastern Time
PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and six months ended June 30, 2006. The net loss for the second quarter of 2006 was $6.9 million, or $0.13 per share, compared with a net loss for the second quarter of
View HTML
Toggle Summary AVI BioPharma Provides Cardiovascular Program Update; Notice of Allowance of Two Patents Strengthens Cardiovascular Restenosis Program
PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 3, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today issued an update on its licensed and internal cardiovascular programs, both of which have been strengthened by notices of allowance from the U.S. Patent Office. AVI licensed its vascular disease program to the
View HTML
Toggle Summary AVI BioPharma Announces 2006 Second Quarter Financial Results Conference Call
PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 1, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today announced that the company will hold a conference call to discuss its 2006 second quarter financial results on Tuesday, August 8, 2006, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
View HTML
Toggle Summary AVI BioPharma Announces Hepatitis C Virus Clinical Study Modification
PORTLAND, Ore.--(BUSINESS WIRE)--July 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) announced today that it has entered patients to fill two new cohorts to extend the duration of treatment with AVI-4065 in its hepatitis C virus (HCV) clinical trial. One cohort will be treated twice daily for 28 days
View HTML
Toggle Summary AVI BioPharma to Present at Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference
PORTLAND, Ore.--(BUSINESS WIRE)--June 19, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), announced that Alan P. Timmins, AVI's president and COO, will present the company's biodefense therapeutic development strategy and progress at the Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity
View HTML
Toggle Summary AVI BioPharma Presents Preclinical Results Preventing and Treating Diabetes Using Its ESPRIT Exon Skipping Technology
PORTLAND, Ore.--(BUSINESS WIRE)--June 5, 2006-- Positive Data Presented at the Prestigious Federation of Clinical Immunology Societies (FOCIS 2006) Annual Meeting AVI BioPharma, Inc. (Nasdaq:AVII), has announced preclinical data evaluating the use of antisense-based exon skipping pre-RNA
View HTML
Toggle Summary AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of Antibiotics
PORTLAND, Ore.--(BUSINESS WIRE)--May 24, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that it has received a Notice of Allowance for U.S. Patent No. 7,049,431 titled "Antisense Antibacterial Cell Division Composition and Method." The patent describes the use of NEUGENE (R) antisense
View HTML
Toggle Summary AVI BioPharma to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference
PORTLAND, Ore.--(BUSINESS WIRE)--May 11, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Monday, May 15, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the Rodman & Renshaw 3rd Annual Global Healthcare Conference,
View HTML
Toggle Summary AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting
PORTLAND, Ore.--(BUSINESS WIRE)--May 10, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) will present initial data from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection at the prestigious International Conference on Antiviral Research (ICAR) annual
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.